Summit 2.0 is advanced molecular testing that analyzes a sample of your cerebrospinal fluid (CSF) to help diagnose central nervous system (CNS) tumors. Because it uses CSF from a routine lumbar puncture, Summit 2.0 can help bridge the gap where other tumor detection options have limitations:

• CSF Cytology: Low sensitivity and often misses detailed genetic information
• Brain Imaging (MRI/CT scans): Can be difficult differentiating cancer from other conditions and lacks molecular data
• Brain Biopsy: Highly invasive with risk of hemorrhage, neurological injury, stroke, death. Sometimes infeasible due to tumor location

Summit 2.0 looks for specific genes and genomic changes associated with brain and spinal cord cancers. Detecting that certain genes are present, or confirming they’re absent, helps indicate the tumor type and whether it may be benign. The genes investigated are listed in your Belay Diagnostics report. Clinicians use test results and guidelines (for example, The National Comprehensive Cancer Network) to help inform diagnosis, select therapies and clinical trials, and monitor treatment. In short, identifying genomic alterations helps your physician detect and manage CNS malignancies.​

Vantage is an additional CSF‑based test that evaluates MGMT promoter methylation status, a biomarker used in certain CNS tumors. A positive MGMT methylation result is generally associated with a more favorable prognosis and can help your care team select therapies where a better response is likely.

Vantage can be ordered together with Summit™ and uses the same CSF specimen, providing complementary information to guide treatment decisions without additional invasive procedures.

If your doctor suspects a CNS tumor, Belay testing may be ordered. The test requires a sample of cerebrospinal fluid (CSF), the clear fluid that cushions the brain and spinal cord. A CSF sample is a commonly ordered test that requires a lumbar puncture or spinal tap. The doctor will complete the test requisition and ask you to sign the informed consent form to expedite the process. Results are typically available in 10-14 days. Your doctor will review your results with you.

Belay Diagnostics is committed to providing advanced testing to all eligible patients. While we are working to secure broad insurance coverage from major payers for our patients, we provide self‑pay options and tiered pricing based on income. Belay testing is a qualified medical expense and HSA (Health Savings Account) and FSA (Flexible Spending Account) apply.

For test information, billing, or any other questions, please contact Belay Customer Service at billing@belaydiagnostics.com, fill out the financial assistance form below, or call 331‑320‑0155 and we will contact you.